Cite
MLA Citation
E. Élez et al.. “Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.” Annals of oncology, vol. 26, n.d., pp. 132–140. http://access.bl.uk/ark:/81055/vdc_100097086180.0x000024